Autoimmunity against type VII collagen in inflammatory bowel disease

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 10, 2010, Pages 2393-2403

  Hundorfean, Gheorghe ^a   Neurath, Markus F ^b   Sitaru, Cassian ^c  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Adhesion molecules; Autoimmunity; Crohn's disease; Epidermolysis bullosa acquisita; T cells, type VII collagen; Ulcerative colitis

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; CELL ADHESION MOLECULE; COLLAGEN TYPE 7;

ANIMAL; ARTICLE; AUTOIMMUNITY; BASEMENT MEMBRANE; CROHN DISEASE; DISEASE MODEL; ENTERITIS; EPIDERMOLYSIS BULLOSA ACQUISITA; EXTRACELLULAR MATRIX; HUMAN; IMMUNOLOGY; INFLAMMATION; METABOLISM; MOUSE; PATHOLOGY; T LYMPHOCYTE; ULCERATIVE COLITIS;

ANIMALS; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNITY; BASEMENT MEMBRANE; CELL ADHESION MOLECULES; COLITIS, ULCERATIVE; COLLAGEN TYPE VII; CROHN DISEASE; DISEASE MODELS, ANIMAL; EPIDERMOLYSIS BULLOSA ACQUISITA; EXTRACELLULAR MATRIX; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; MICE; T-LYMPHOCYTES;

EID: 77958567994     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00959.x     Document Type: Article

References (154)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002; 347: 417-29.
2. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest. 2007; 117: 514-21.
3. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007; 448: 427-34.
4. Sitaru C, Goebeler M, Zillikens D. Bullous autoimmune dermatoses (I): pathogenesis and diagnosis. J Dtsch Dermatol Ges. 2004; 2: 123-8.
5. Mihai S, Sitaru C. Immunopathology and molecular diagnosis of autoimmune bullous diseases. J Cell Mol Med. 2007; 11: 462-81.
6. Zhu XJ, Niimi Y, Bystryn JC. Epidermolysis bullosa acquisita. Incidence in patients with basement membrane zone antibodies. Arch Dermatol. 1990; 126: 171-4.
7. Bernard P, Vaillant L, Labeille B, et al Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. Arch Dermatol. 1995; 131: 48-52.
8. Wong SN, Chua SH. Spectrum of subepidermal immunobullous disorders seen at the National Skin Centre, Singapore: a 2-year review. Br J Dermatol. 2002; 147: 476-80.
9. Nanda A, Dvorak R, Al-Saeed K, et al Spectrum of autoimmune bullous diseases in Kuwait. Int J Dermatol. 2004; 43: 876-81.
10. Dotson AD, Raimer SS, Pursley TV, et al Systemic lupus erythematosus occurring in a patient with epidermolysis bullosa acquisita. Arch Dermatol. 1981; 117: 422-6.
11. Chan LS, Lapiere JC, Chen M, et al Bullous systemic lupus erythematosus with autoantibodies recognizing multiple skin basement membrane components, bullous pemphigoid antigen 1, laminin-5, laminin-6, and type VII collagen. Arch Dermatol. 1999; 135: 569-73.
12. Herrero-González JE, Mascaró JMJ, Herrero C, et al Autoantibodies from patients with BSLE inducing recruitment of leukocytes to the dermoepidermal junction and subepidermal splits in cryosections of human skin. Arch Dermatol. 2006; 142: 1513-6.
13. Harris-Stith R, Erickson QL, Elston DM, et al Bullous eruption: a manifestation of lupus erythematosus. Cutis. 2003; 72: 31-7.
14. Eckman JA, Mutasim DF. Bullous systemic lupus erythematosus with milia and calcinosis. Cutis. 2002; 70: 31-4.
15. Shirahama S, Yagi H, Furukawa F, et al A case of bullous systemic lupus erythematosus. Dermatology. 1994; 189: 95-6.
16. Shirahama S, Furukawa F, Yagi H, et al Bullous systemic lupus erythematosus: detection of antibodies against noncollagenous domain of type VII collagen. J Am Acad Dermatol. 1998; 38: 844-8.
17. Yell JA, Wojnarowska F, Allen J, et al Bullous systemic lupus erythematosus - a variable disease. Lupus. 1993; 2: 383-5.
18. Yell JA, Allen J, Wojnarowska F, et al Bullous systemic lupus erythematosus: revised criteria for diagnosis. Br J Dermatol. 1995; 132: 921-8.
19. Yell JA, Wojnarowska F. Bullous skin disease in lupus erythematosus. Lupus. 1997; 6: 112-21.
20. Chan L, Woodley D. Epidermolysis bullosa acquisita in the elderly. J Geriatr Dermatol. 1995; 4: 47-52.
21. Krivo JM, Miller F. Immunopathology of epidermolysis bullosa acquisita. Association with mixed cryoglobulinemia. Arch Dermatol. 1978; 114: 1218-20.
22. Hoshina D, Sawamura D, Nomura T, et al Epidermolysis bullosa acquisita associated with psoriasis vulgaris. Clin Exp Dermatol. 2007; 32: 516-8.
23. Endo Y, Tamura A, Ishikawa O, et al Psoriasis vulgaris coexistent with epidermolysis bullosa acquisita. Br J Dermatol. 1997; 137: 783-6.
24. Kirtschig G, Chow ET, Venning VA, et al Acquired subepidermal bullous diseases associated with psoriasis: a clinical, immunopathological and immunogenetic study. Br J Dermatol. 1996; 135: 738-45.
25. Chen M, O'Toole EA, Sanghavi J, et al The epidermolysis bullosa acquisita antigen (type VII collagen) is present in human colon and patients with Crohn's disease have autoantibodies to type VII collagen. J Invest Dermatol. 2002; 118: 1059-64.
26. Hughes BR, Horne J. Epidermolysis bullosa acquisita and total ulcerative colitis. J R Soc Med. 1988; 81: 473-5.
27. Lohi J, Leivo I, Tani T, et al Laminins, tenascin and type VII collagen in colorectal mucosa. Histochem J. 1996; 28: 431-40.
28. Paller AS, Queen LL, Woodley DT, et al Organ-specific, phylogenetic, and ontogenetic distribution of the epidermolysis bullosa acquisita antigen. J Invest Dermatol. 1986; 86: 376-9.
29. Visser R, Arends JW, Leigh IM, et al Patterns and composition of basement membranes in colon adenomas and adenocarcinomas. J Pathol. 1993; 170: 285-90.
30. Sitaru C, Mihai S, Otto C, et al Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen. J Clin Invest. 2005; 115: 870-8.
31. Sitaru C. Experimental models of epidermolysis bullosa acquisita. Exp Dermatol. 2007; 16: 520-31.
32. Parente MG, Chung LC, Ryynanen J, et al Human type VII collagen: cDNA cloning and chromosomal mapping of the gene. Proc Natl Acad Sci USA. 1991; 88: 6931-5.
33. Bentz H, Morris NP, Murray LW, et al Isolation and partial characterization of a new human collagen with an extended triple-helical structural domain. Proc Natl Acad Sci USA. 1983; 80: 3168-72.
34. Keene DR, Sakai LY, Lunstrum GP, et al Type VII collagen forms an extended network of anchoring fibrils. J Cell Biol. 1987; 104: 611-21.
35. Morris NP, Keene DR, Glanville RW, et al The tissue form of type VII collagen is an antiparallel dimer. J Biol Chem. 1986; 261: 5638-44.
36. Sakai LY, Keene DR, Morris NP, et al Type VII collagen is a major structural component of anchoring fibrils. J Cell Biol. 1986; 103: 1577-86.
37. Christiano AM, Greenspan DS, Hoffman GG, et al A missense mutation in type VII collagen in two affected siblings with recessive dystrophic epidermolysis bullosa. Nat Genet. 1993; 4: 62-6.
38. Heinonen S, Männikkö M, Klement JF, et al Targeted inactivation of the type VII collagen gene (Col7a1) in mice results in severe blistering phenotype: a model for recessive dystrophic epidermolysis bullosa. J Cell Sci. 1999; 112: 3641-8.
39. Fritsch A, Loeckermann S, Kern J, et al A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy. J Clin Invest. 2008; 118: 1669-79.
40. Roenigk HHJ, Ryan JG, Bergfeld WF. Epidermolysis bullosa acquisita. Report of three cases and review of all published cases. Arch Dermatol. 1971; 103: 1-10.
41. Yaoita H, Briggaman RA, Lawley TJ, et al Epidermolysis bullosa acquisita: ultrastructural and immunological studies. J Invest Dermatol. 1981; 76: 288-92.
42. Gammon WR, Briggaman RA, Inman AO, et al Differentiating anti-lamina lucida and anti-sublamina densa anti-BMZ antibodies by indirect immunofluorescence on 1.0 M sodium chloride-separated skin. J Invest Dermatol. 1984; 82: 139-44.
43. Fine JD, Tyring S, Gammon WR. The presence of intra-lamina lucida blister formation in epidermolysis bullosa acquisita: possible role of leukocytes. J Invest Dermatol. 1989; 92: 27-32.
44. Sitaru C, Kromminga A, Hashimoto T, et al Autoantibodies to type VII collagen mediate Fcγ-dependent neutrophil activation and induce dermal-epidermal separation in cryosections of human skin. Am J Pathol. 2002; 161: 301-11.
45. Shimanovich I, Mihai S, Oostingh GJ, et al Granulocyte-derived elastase and gelatinase B are required for dermal-epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid. J Pathol. 2004; 204: 519-27.
46. Chiriac MT, Roesler J, Sindrilaru A, et al NADPH oxidase is required for neutrophil-dependent autoantibody-induced tissue damage. J Pathol. 2007; 212: 56-65.
47. Sitaru C, Chiriac MT, Mihai S, et al Induction of complement-fixing autoantibodies against type VII collagen results in subepidermal blistering in mice. J Immunol. 2006; 177: 3461-8.
48. Sesarman A, Sitaru AG, Olaru F, et al Neonatal Fc receptor deficiency protects from tissue injury in experimental epidermolysis bullosa acquisita. J Mol Med. 2008; 86: 951-9.
49. Sesarman A, Mihai S, Chiriac MT, et al Binding of avian IgY to type VII collagen does not activate complement and leucocytes and fails to induce subepidermal blistering in mice. Br J Dermatol. 2008; 158: 463-71.
50. Hertl M, Eming R, Veldman C. T cell control in autoimmune bullous skin disorders. J Clin Invest. 2006; 116: 1159-66.
51. Sitaru A, Sesarman A, Mihai S, et al T cells are required for the production of blister-inducing autoantibodies in experimental epidermolysis bullosa acquisita. submitted
52. Mihai S, Chiriac MT, Takahashi K, et al The alternative pathway of complement activation is critical for blister induction in experimental epidermolysis bullosa acquisita. J Immunol. 2007; 178: 6514-21.
53. Rose NR, Bona C. Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunol Today. 1993; 14: 426-30.
54. Wen Z, Fiocchi C. Inflammatory bowel disease: autoimmune or immune-mediated pathogenesis Clin Dev Immunol. 2004; 11: 195-204.
55. Podolsky DK. The current future understanding of inflammatory bowel disease. Best Pract Res Clin Gastroenterol. 2002; 16: 933-43.
56. Braegger CP. Immunopathogenesis of chronic inflammatory bowel disease. Acta Paediatr Suppl. 1994; 83: 18-21.
57. Marks DJB, Segal AW. Innate immunity in inflammatory bowel disease: a disease hypothesis. J Pathol. 2008; 214: 260-6.
58. Marks DJB, Rahman FZ, Sewell GW, et al Crohn's disease: an immune deficiency state. Clin Rev Allergy Immunol. 2009; DOI 10.1007/s12016-009-8133-2.
59. Colombel J, Watson AJM, Neurath MF. The 10 remaining mysteries of inflammatory bowel disease. Gut. 2008; 57: 429-33.
60. Neurath MF, Finotto S, Glimcher LH. The role of Th1/Th2 polarization in mucosal immunity. Nat Med. 2002; 8: 567-73.
61. Strober W. Animal models of inflammatory bowel disease - an overview. Dig Dis Sci. 1985; 30: 3S-10S.
62. Hoffmann JC, Pawlowski NN, Kühl AA, et al Animal models of inflammatory bowel disease: an overview. Pathobiology. 20022003; 70: 121-30.
63. Mizoguchi A, Mizoguchi E, Bhan AK. Immune networks in animal models of inflammatory bowel disease. Inflamm Bowel Dis. 2003; 9: 246-59.
64. Mizoguchi A, Mizoguchi E. Inflammatory bowel disease, past, present and future: lessons from animal models. J Gastroenterol. 2008; 43: 1-17.
65. Elson CO, Cong Y, Lorenz R, et al New developments in experimental models of inflammatory bowel disease. Curr Opin Gastroenterol. 2004; 20: 360-7.
66. Elson CO, Cong Y, McCracken VJ, et al Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota. Immunol Rev. 2005; 206: 260-76.
67. Wirtz S, Neurath MF. Mouse models of inflammatory bowel disease. Adv Drug Deliv Rev. 2007; 59: 1073-83.
68. Danzi JT. Extraintestinal manifestations of idiopathic inflammatory bowel disease. Arch Intern Med. 1988; 148: 297-302.
69. Ardizzone S, Puttini PS, Cassinotti A, et al Extraintestinal manifestations of inflammatory bowel disease. Dig Liver Dis. 2008; 40: S253-9.
70. Fricke H, Birkhofer A, Folwaczny C, et al Characterization of antigens from the human exocrine pancreatic tissue (Pag) relevant as target antigens for autoantibodies in Crohn's disease. Eur J Clin Invest. 1999; 29: 41-5.
71. Aichbichler BW, Petritsch W, Reicht GA, et al Anti-cardiolipin antibodies in patients with inflammatory bowel disease. Dig Dis Sci. 1999; 44: 852-6.
72. Mayet WJ, Wandel E, Hermann E, et al Antibodies to cytoskeletal components in patients undergoing long-term hemodialysis detected by a sensitive enzyme-linked immunosorbent assay (ELISA). Clin Nephrol. 1990; 33: 272-8.
73. Saxon A, Shanahan F, Landers C, et al A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol. 1990; 86: 202-10.
74. Duerr RH, Targan SR, Landers CJ, et al Anti-neutrophil cytoplasmic antibodies in ulcerative colitis. Comparison with other colitides/diarrheal illnesses. Gastroenterology. 1991; 100: 1590-6.
75. Duerr RH, Targan SR, Landers CJ, et al Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis. Gastroenterology. 1991; 100: 1385-91.
76. McKenzie H, Main J, Pennington CR, et al Antibody to selected strains of Saccharomyces cerevisiae (baker's and brewer's yeast) and Candida albicans in Crohn's disease. Gut. 1990; 31: 536-8.
77. Doe WF, Booth CC, Brown DL. Evidence for complement-binding immune complexes in adult coeliac disease, Crohn's disease, and ulcerative colitis. Lancet. 1973; 1: 402-3.
78. Jewell DP, MacLennan IC. Circulating immune complexes in inflammatory bowel disease. Clin Exp Immunol. 1973; 14: 219-26.
79. Halstensen TS, Das KM, Brandtzaeg P. Epithelial deposits of immunoglobulin G1 and activated complement colocalise with the M(r) 40 kD putative autoantigen in ulcerative colitis. Gut. 1993; 34: 650-7.
80. Wucherpfennig KW. Mechanisms for the induction of autoimmunity by infectious agents. J Clin Invest. 2001; 108: 1097-104.
81. Vezys V, Lefrançois L. Cutting edge: inflammatory signals drive organ-specific autoimmunity to normally cross-tolerizing endogenous antigen. J Immunol. 2002; 169: 6677-80.
82. Ricart E, Panaccione R, Loftus EVJ, et al Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study. Inflamm Bowel Dis. 2004; 10: 207-14.
83. Schrumpf E, Boberg K. Epidemiology of primary sclerosing cholangitis. Best practice & research. 2001; 15: 553-62.
84. Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut. 1998; 42: 387-91.
85. Wakefield AJ, Sawyerr AM, Dhillon AP, et al Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction. Lancet. 1989; 2: 1057-62.
86. Wakefield AJ, Sankey EA, Dhillon AP, et al Granulomatous vasculitis in Crohn's disease. Gastroenterology. 1991; 100: 1279-87.
87. Seibold F, Weber P, Jenss H, et al Autoimmune hepatitis in inflammatory bowel disease: report of two unusual cases. Z Gastroenterol. 1997; 35: 29-32.
88. Heikius B, Niemelä S, Lehtola J, et al Elevated pancreatic enzymes in inflammatory bowel disease are associated with extensive disease. Am J Gastroenterol. 1999; 94: 1062-9.
89. McCallum DI, Kinmont PD. Dermatological manifestations of Crohn's disease. Br J Dermatol. 1968; 80: 1-8.
90. Basler RS. Ulcerative colitis and the skin. Med Clin North Am. 1980; 64: 941-54.
91. Farmer RG, Hawk WA, Turnbull RBJ. Clinical patterns in Crohn's disease: a statistical study of 615 cases. Gastroenterology. 1975; 68: 627-35.
92. Mir-Madjlessi SH, Forouzandeh B, Ghadimi R. Ulcerative colitis in Iran: a review of 112 cases. Am J Gastroenterol. 1985; 80: 862-6.
93. Feliciani C, De Simone C, Amerio P. Dermatological signs during inflammatory bowel diseases. Eur Rev Med Pharmacol Sci. 2009; 13: 15-21.
94. Gregory B, Ho VC. Cutaneous manifestations of gastrointestinal disorders. Part I. J Am Acad Dermatol. 1992; 26: 153-66.
95. Blitz NM, Rudikoff D. Pyoderma gangrenosum. Mt Sinai J Med. 2001; 68: 287-97.
96. Solley GO, Winklemann RK, Rovelstad RA. Correlation between regional enterocolitis and cutaneous polyarteritis nodosa. Two case reports and review of the literature. Gastroenterology. 1975; 69: 235-9.
97. Samitz MH, Greenberg MS. Skin lesions in association with ulcerative colitis. Gastroenterology. 1951; 19: 476-9.
98. Lee FI, Bellary SV, Francis C. Increased occurrence of psoriasis in patients with Crohn's disease and their relatives. Am J Gastroenterol. 1990; 85: 962-3.
99. Cheesbrough MJ. Epidermolysis bullosa acquisita and Crohn's disease. Br J Dermatol. 1978; 99: 53-4.
100. Oostingh GJ, Sitaru C, Zillikens D, et al Subclass distribution of type VII collagen-specific autoantibodies in patients with inflammatory bowel disease. J Dermatol Sci. 2005; 37: 182-4.
101. Shivananda S, Lennard-Jones J, Logan R, et al Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut. 1996; 39: 690-7.
102. Braun J, Wei B. Body traffic: ecology, genetics, and immunity in inflammatory bowel disease. Annu Rev Pathol. 2007; 2: 401-29.
103. Gammon WR, Heise ER, Burke WA, et al Increased frequency of HLA-DR2 in patients with autoantibodies to epidermolysis bullosa acquisita antigen: evidence that the expression of autoimmunity to type VII collagen is HLA class II allele associated. J Invest Dermatol. 1988; 91: 228-32.
104. Lee CW, Kim SC, Han H. Distribution of HLA class II alleles in Korean patients with epidermolysis bullosa acquisita. Dermatology. 1996; 193: 328-9.
105. Mihai S, Chiriac MT, Herrero-González JE, et al IgG4 autoantibodies induce dermal-epidermal separation. J Cell Mol Med. 2007; 11: 1117-28.
106. Sitaru C, Mihai S, Zillikens D. The relevance of the IgG subclass of autoantibodies for blister induction in autoimmune bullous skin diseases. Arch Dermatol Res. 2007; 299: 1-8.
107. Sherry-Dottridge F. Case for diagnosis: acquired epidermatolysis bullosa Proc R Soc Med. 1962; 55: 409.
108. Kushniruk W. The immunopathology of epidermolysis bullosa acquisita. Can Med Assoc J. 1973; 108: 1143-6.
109. Raab B, Fretzin DF, Bronson DM, et al Epidermolysis bullosa acquisita and inflammatory bowel disease. JAMA. 1983; 250: 1746-8.
110. Dupont A, Bourlond A, Poncé R. Bullous epidermolysis of late appearance and Crohn's ileitis. Bull Soc Fr Dermatol Syphiligr. 1969; 76: 311-2.
111. Spraul CW, Buchwald H, Lang GK, et al Recurrent corneal ulcer in a patient with Crohn's disease associated with epidermolysis bullosa acquisita. Klin Monatsbl Augenheilkd. 2003; 220: 423-6.
112. Gluck M, Kayne A. Acquired epidermolysis bullosa and Crohn's disease. Gastrointest Endosc. 2003; 57: 563-4.
113. Labeille B, Gineston JL, Denoeux JP, et al Epidermolysis bullosa acquisita and Crohn's disease. A case report with immunological and electron microscopic studies. Arch Intern Med. 1988; 148: 1457-9.
114. Schattenkirchner S, Lémann M, Prost C, et al Localized epidermolysis bullosa acquisita of the esophagus in a patient with Crohn's disease. Am J Gastroenterol. 1996; 91: 1657-9.
115. Españ241;a A, Sitaru C, Pretel M, et al Erythema gyratum repens-like eruption in a patient with epidermolysis bullosa acquisita associated with ulcerative colitis. Br J Dermatol. 2007; 156: 773-5.
116. Pegum JS, Wright JT. Epidermolysis bullosa acquisita and Crohn's disease. Proc R Soc Med. 1973; 66: 234.
117. Metz G, Metz J, Frank H. Acquired epidermolysis bullosa in Crohn's disease. Hautarzt. 1975; 26: 321-6.
118. Livden JK, Nilsen R, Thunold S, et al Epidermolysis bullosa acquisita and Crohn's disease. Acta Derm Venereol. 1978; 58: 241-4.
119. Chouvet B, Guillet G, Perrot H, et al Acquired epidermolysis bullosa with Crohn's disease. Report of two cases and review of literature (author's transl). Ann Dermatol Venereol. 1982; 109: 53-63.
120. Chan LS, Vanderlugt CJ, Hashimoto T, et al Epitope spreading: lessons from autoimmune skin diseases. J Invest Dermatol. 1998; 110: 103-9.
121. Vanderlugt CJ, Miller SD. Epitope spreading. Curr Opin Immunol. 1996; 8: 831-6.
122. Vanderlugt CL, Begolka WS, Neville KL, et al The functional significance of epitope spreading and its regulation by co-stimulatory molecules. Immunol Rev. 1998; 164: 63-72.
123. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol. 2002; 2: 85-95.
124. Goebeler M, Sitaru C, Zillikens D. Bullous autoimmune diseases (II): therapy. J Dtsch Dermatol Ges. 2004; 2: 774-93.
125. Hertl M. Research in practice: Treatment of autoimmune bullous disorders. J Dtsch Dermatol Ges. 2009; 7: 500-5.
126. Hughes AP, Callen JP. Epidermolysis bullosa acquisita responsive to dapsone therapy. J Cutan Med Surg. 2001; 5: 397-9.
127. Arora KP, Sachdeva B, Singh N, et al Remission of recalcitrant epidermolysis bullosa acquisita (EBA) with colchicine monotherapy. J Dermatol. 2005; 32: 114-9.
128. Bauer JW, Schaeppi H, Metze D, et al Ocular involvement in IgA-epidermolysis bullosa acquisita. Br J Dermatol. 1999; 141: 887-92.
129. Berbis P, Privat Y. Value of colchicine in treating acquired epidermolysis bullosa. Ann Dermatol Venereol. 1989; 116: 301-7.
130. Cunningham BB, Kirchmann TT, Woodley D. Colchicine for epidermolysis bullosa acquisita. J Am Acad Dermatol. 1996; 34: 781-4.
131. Megahed M, Scharffetter-Kochanek K. Epidermolysis bullosa acquisita - successful treatment with colchicine. Arch Dermatol Res. 1994; 286: 35-46.
132. Maize JCJ, Cohen JB. Cyclosporine controls epidermolysis bullosa acquisita co-occurring with acquired factor VIII deficiency. Int J Dermatol. 2005; 44: 692-4.
133. Crow LL, Finkle JP, Gammon WR, et al Clearing of epidermolysis bullosa acquisita with cyclosporine. J Am Acad Dermatol. 1988; 19: 937-42.
134. Kowalzick L, Suckow S, Ziegler H, et al Mycophenolate mofetil in epidermolysis bullosa acquisita. Dermatology. 2003; 207: 332-4.
135. Niedermeier A, Eming R, Pfütze M, et al Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies). Arch Dermatol. 2007; 143: 192-8.
136. Crichlow SM, Mortimer NJ, Harman KE. A successful therapeutic trial of rituximab in the treatment of a patient with recalcitrant, high-titre epidermolysis bullosa acquisita. Br J Dermatol. 2007; 156: 194-6.
137. Sadler E, Schafleitner B, Lanschuetzer C, et al Treatment-resistant classical epidermolysis bullosa acquisita responding to rituximab. Br J Dermatol. 2007; 157: 417-9.
138. Wallet-Faber N, Franck N, Batteux F, et al Epidermolysis bullosa acquisita following bullous pemphigoid, successfully treated with the anti-CD20 monoclonal antibody rituximab. Dermatology. 2007; 215: 252-5.
139. Sandborn W. Current directions in IBD therapy: what goals are feasible with biologic modifiers Gastroenterology. 2008; 135: 1442-7.
140. Hanauer S, Schwartz J, Robinson M, et al Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol. 1993; 88: 1188-97.
141. Hanauer SB, Krawitt EL, Robinson M, et al Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Pentasa Crohn's Disease Compassionate Use Study Group. Am J Gastroenterol. 1993; 88: 1343-51.
142. Faubion WAJ, Loftus EVJ, Harmsen WS, et al The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001; 121: 255-60.
143. Bouhnik Y, Lémann M, Mary JY, et al Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet. 1996; 347: 215-9.
144. Present DH, Korelitz BI, Wisch N, et al Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med. 1980; 302: 981-7.
145. Feagan BG, Rochon J, Fedorak RN, et al Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med. 1995; 332: 292-7.
146. Oren R, Arber N, Odes S, et al Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology. 1996; 110: 1416-21.
147. Feagan BG, McDonald JW. Cyclosporin in Crohn's disease. Lancet. 1997; 349: 1328.
148. Palestine RF, Kossard S, Dicken CH. Epidermolysis bullosa acquisita: a heterogeneous disease. J Am Acad Dermatol. 1981; 5: 43-53.
149. Ray TL, Levine JB, Weiss W, et al Epidermolysis bullosa acquisita and inflammatory bowel disease. J Am Acad Dermatol. 1982; 6: 242-52.
150. Sheridan R, Robbins S, Elston D, et al Resolution of epidermolysis bullosa aquisita with resection of intraabdominal Crohn's disease. Mil Med. 1987; 152: 368-9.
151. Anex R, Rybojad M, Prost C. Epidermolyse bulleuse acquise et maladie de Crohn. A Propos d'une observation. Nouv Dermatol. 1994; 13: 27-9.
152. Van't Veen AJ, Heule F, Vuzevski VD, et al Epidermolysis bullosa acquisita. Br J Dermatol. 1994; 131: 724-5.
153. Al-Ratrout JT, Ansari NA. Epidermolysis bullosa acquisita and Crohn's disease. Saudi Med J. 2004; 25: 1736-8.
154. Vicente EF, Hernández-Núñez A, Aspa J, et al Crohn's disease, relapsing polychondritis and epidermolysis bullosa acquisita: an immune-mediated inflammatory syndrome. Rheumatology. 2008; 47: 380-1.